Earnings Flash (IPAR) Interparfums, Inc. Reports Q2 Revenue $341.0M, vs. FactSet Est of $341.0M

Interparfums (IPAR) reported Q2 revenue of $341.0M, matching a FactSet estimate of $341.0M. The company said it expects full-year 2026 revenue of $1.48B, compared with a FactSet consensus of $1.50B, and maintained its 2026 outlook, according to the company.

Original reporting
Published Aug 4, 2026, 8:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$IPAR
Neutral
medium confidence
Mentioned
$IPAR
Relevance
6/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$IPARNeutralLow
01

Why it matters

For trading, the key decision point is whether the maintained 2026 revenue outlook changes the market’s forward expectations; with Q2 revenue matching consensus, the incremental information is mainly the confirmation of guidance.

02

Market read

In-line Q2 revenue and maintained guidance typically reduce the probability of a large fundamental repricing, shifting attention to any details not captured in the flash.

03

What to watch

The article does not include EPS, margin, or segment performance; traders may need the full earnings release to assess whether the maintained outlook reflects genuine stability or offsetting pressures.

Relevance 6/10Novelty 4/10Timing: after-hours earnings release (Aug. 4, 2026)

Background

The piece is an earnings flash summarizing Interparfums Q2 revenue versus FactSet and reiterating full-year 2026 revenue expectations.

Company-level read

Ticker impact

$IPARNeutralMedium confidence
Context

Interparfums reported Q2 revenue of $341.0M, matching the FactSet estimate, and maintained its 2026 outlook.

Expected impact

Likely modest reaction, with follow-through depending on how investors interpret the maintained 2026 revenue outlook versus expectations.

Evidence & confidence

The article provides an in-line Q2 revenue number and states full-year 2026 revenue guidance is maintained, which typically reduces upside/downside surprise versus a beat or raise.

Market effects

Limited read-through to the broader fragrance/personal-care sector because the disclosure is primarily company-specific and guidance is unchanged.

No clear regional spillover indicated beyond the single-name earnings update.

Minimal global market relevance; this is a single-company earnings flash with no new macro or cross-border catalyst mentioned.

Counterpoint

Even with in-line revenue, investors may focus on any omitted details (margins, EPS, demand trends) not included in this scrape, which could still drive a larger move than the headline implies.

Key entities

  • Interparfums, Inc.

    Reported Q2 revenue of $341.0M versus FactSet $341.0M and maintained 2026 outlook, expecting full-year 2026 revenue of $1.48B versus $1.50B estimate.

Related articles

$IPARMed

Inter Parfums (NASDAQ:IPAR) Posts Better

Inter Parfums (NASDAQ:IPAR) reported Q2 CY2026 revenue of $341 million, up 2.1% year on year and 0.6% above market expectations, according to the company. Full-year revenue guidance was $1.48 billion at the midpoint, 1.5% below analysts’ estimates. GAAP EPS was $0.95, 2.1% below consensus. The stock was flat at $128.43 after results.

$IPARMed

INTERPARFUMS INC (IPAR): Results of Operations and Financial Condition

INTERPARFUMS INC (IPAR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 7 ex991_1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE INTERPARFUMS, INC. REPORTS 2026 SECOND QUARTER NET SALES 2026 Second Quarter Conference Call Scheduled for August 5, 2026 New York, New York, July 22, 2026, Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums”

$NVDAMed

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Broadcom, Microsoft, IBM, Meta, Tyson Foods & more

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.